xbrli:pureiso4217:DKK332576352022-01-012022-12-31332576352022-01-012022-12-311332576352022-01-012022-12-311332576352022-01-012022-12-31332576352021-01-012021-12-31332576352022-01-012022-12-31fsa:ProposedDividendRecognisedInEquityMember332576352021-01-012021-12-31fsa:ProposedDividendRecognisedInEquityMember332576352022-01-012022-12-31fsa:RetainedEarningsMember332576352021-01-012021-12-31fsa:RetainedEarningsMember332576352022-01-012022-12-31fsa:RetainedEarningsMember332576352022-01-012022-12-31fsa:ProposedDividendRecognisedInEquityMember332576352022-12-31332576352021-12-31332576352022-01-01fsa:ContributedCapitalMember332576352022-01-01fsa:RetainedEarningsMember332576352022-01-01fsa:ProposedDividendRecognisedInEquityMember332576352022-01-01332576352022-12-31fsa:ContributedCapitalMember332576352022-12-31fsa:RetainedEarningsMember332576352022-12-31fsa:ProposedDividendRecognisedInEquityMemberGrundlag for konklusionKonklusion2023-04-242023-04-24true2021-01-012021-12-3133963556København S23006WeidekampsgadeDeloitte Statsautoriseret RevisionspartnerselskabKøbenhavnKøbenhavn V1634Regnskabsklasse BErklæring om udvidet gennemgang2022-12-312022-01-012<br /><br />16Rosenørns AlléJJ Pharma Consult ApS33257635339635562300 København SWeidekampsgade 6Deloitte Statsautoriseret RevisionspartnerselskabÅrsrapportThe Executive Board has today considered and approved the annual report of JJ Pharma Consult ApS for the financial year 01.01.2022 - 31.12.2022. The annual report is presented in accordance with the Danish Financial Statements Act.In my opinion, the financial statements give a true and fair view of the Entity’s financial position at 31.12.2022 and of the results of its operations for the financial year 01.01.2022 - 31.12.2022.I believe that the management commentary contains a fair review of the affairs and conditions referred to
therein.I recommend the annual report for adoption at the Annual General Meeting.CopenhagenJack Groth JacobsenTo the shareholders of JJ Pharma Consult ApSWe have performed an extended review of the financial statements of JJ Pharma Consult ApS for the
financial year 01.01.2022 - 31.12.2022, which comprise the income statement,
balance sheet, statement of
changes in equity and notes, including a summary of significant
accounting policies. The financial statements
are prepared in accordance with the Danish Financial Statements Act.
Based on our extended review, in our opinion, the financial statements give a true and fair view of the Entity’s
financial position at. 31.12.2022 and of the results of its operations for the
financial year 01.01.2022 - 31.12.2022 in accordance with the Danish Financial
Statements Act.We conducted our extended review in accordance with the assurance engagement standard for small enterprises
as issued by the Danish Business Authority and the standard on extended review of financial statements
prepared in accordance with the Danish Financial Statements Act as issued by FSR - Danish Auditors.
Our responsibilities under those standards and requirements are further described in the ”Auditor’s responsibilities
for the extended review of the financial statements” section. We are independent of the Entity in accordance with the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the evidence we have obtained is
sufficient and appropriate to provide a basis for our conclusion.Management is responsible for the preparation of financial statements that give a true and fair view in accordance
with the Danish Financial Statements Act, and for such internal control as Management determines
is necessary to enable the preparation of financial statements that are free from material misstatement,
whether due to fraud or error.
In preparing the financial statements, Management is responsible for assessing the Entity’s ability to continue
as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless Management either intends to liquidate the Entity or to cease operations, or has
no realistic alternative but to do so.Our responsibility is to express a conclusion on the financial statements. This requires that we plan and
perform procedures to obtain limited assurance about our conclusion on the financial statements and that
we also perform specifically required supplementary procedures for the purpose of obtaining additional assurance
about our conclusion.
An extended review consists of making inquiries, primarily of Management and, if appropriate, of other entity
personnel, performing analytical and the specifically required supplementary procedures as well as evaluating
the evidence obtained.
The procedures performed in an extended review are less in scope than in an audit, and accordingly we do
not express an audit opinion on the financial statements.Management is responsible for the management commentary.
Our conclusion on the financial statements does not cover the management commentary, and we do not express
any form of assurance conclusion thereon.
In connection with our extended review of the financial statements our responsibility is to read the management
commentary and, in doing so, consider whether the management commentary is materially inconsistent
with the financial statements or our knowledge obtained in the extended review or otherwise appears to be
materially misstated.
Moreover, it is our responsibility to consider whether the management commentary provides the information
required under the Danish Financial Statements Act.<br />Based on the work we have performed, we conclude that the management commentary is in accordance with
financial statements and has been prepared in accordance with the requirements of the Danish Financial
Statements Act. We did not identify any material misstatement of the management commentary.CopenhagenJan Larsenmne16541State Authorised Public AccountantPrimary activitiesThe Entity’s activities comprise commercial business
and shareholding in other enterprises.Development in activities and financesThe performance for the year is as expected.Events after the balance sheet dateThe Entity has after year-end sold the interest in S-cubed ApS with a profit. No other events have occurred after the balance sheet date to this date, which would influence the evaluation of
this annual report.-19376-144194000004041031022031480-106454031195639479708-680347093481479708-5868660006086479708-5929521000000113000-520292-705952-520292100000077735477735477735477735477735477735497697613079014055976443080111465044308011146501136380142372159351512579982370869203535280000800001277769179806110000001130002357769199106180000179806111300019910618000012777691000000131001310003119113100442911310044291237086920353520-113000-1130001 Other financial income
2022
DKK2021
DKKFair value adjustments42,7510Other financial income59,452148102,2031482 Other financial expenses2022
DKK2021
DKKOther interest expenses1,3182,774Other financial expenses1,8012,8653,1195,639<br />2022
DKK2021
DKKOther interest expenses1,3182,774Other financial expenses1,8012,8653,1195,6393 Financial assetsInvestments in
associates
DKKCost beginning of year1,841,894Disposals(1,041,894)Cost end of year800,000Impairment losses beginning of year(1,064,540)Reversal regarding disposals1,041,894Impairment losses end of year(22,646)Carrying amount end of year777,354The result for S-Cubed ApS for 2022 is not yet avilable, which is why the information below relates to the annual report for 2021.Investments in associatesRegistered inCorporate
formEquity
interest
%Equity
DKKProfit/loss
DKKS-cubed ApS (annual report for 2021)VærløseApS203,886,769400,7260This annual report has been presented in accordance with the provisions of the Danish Financial Statements
Act governing reporting class B enterprises with addition of a few provisions for reporting class C.The accounting policies applied to these financial statements are consistent with those applied last year.falseRecognition and measurementAssets are recognised in the balance sheet when it is probable as a result of a prior event that future economic
benefits will flow to the Entity, and the value of the asset can be measured reliably.
Liabilities are recognised in the balance sheet when the Entity has a legal or constructive obligation as a
result of a prior event, and it is probable that future economic benefits will flow out of the Entity, and the
value of the liability can be measured reliably.
On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial
recognition is effected as described below for each financial statement item.
Anticipated risks and losses that arise before the time of presentation of the annual report and that confirm
or invalidate affairs and conditions existing at the balance sheet date are considered at recognition and
measurement.
Income is recognised in the income statement when earned, whereas costs are recognised by the amounts
attributable to this financial year.Gross profit or lossGross profit or loss comprises other external expenses.Fair value adjustments of other investment assetsFair value adjustments of other investment assets comprise adjustments for the financial year of the Entity’s
investment assets measured at fair value at the balance sheet date.Other external expensesOther external expenses include expenses relating to the Entity’s ordinary activities, including expenses for
premises, stationery and office supplies etc. This item also includes writedowns of receivables recognised in current assets.Income from investments in associatesIncome from investments in associates comprises dividends etc received from the individual
associates in the financial year.Other financial incomeOther financial income comprises interest income etc.Impairment losses on financial assetsImpairment losses on financial assets comprise impairment losses on financial assets which are not measured
at fair value on a current basis.Other financial expensesOther financial expenses comprise interest expenses etc.Tax on profit/loss for the yearTax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the
income statement by the portion attributable to the profit for the year and recognised directly in equity by
the portion attributable to entries directly in equity.Other taxesThe item includes tax amounts calculated on a basis other than income for the year, which are not refunded
to the Entity.Investments in associatesInvestments in associates are measured at cost. Investments are written down to the lower
of recoverable amount and carrying amount.Investments in associates fall within the definitions of both participating interests and associates, yet in the financial statements they have been presented as investments in associates because this designation reflects more accurately the Company’s involvement in the relevant entities.
The accounting policies applied to material financial statement items of associates are:
Other investments comprising listed securities and #unlisted investments are measured at fair value.
ReceivablesReceivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and
doubtful debts.Tax payable or receivableCurrent tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's
taxable income, adjusted for prepaid tax.Other investmentsOther current asset investments comprise listed securities measured at fair value (market price) at the
balance sheet date.CashCash comprises bank deposits.DividendDividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for
the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial
year is recognised directly in equity when distributed and disclosed as a separate item in Management's
proposal for distribution of profit/loss.Other financial liabilitiesOther financial liabilities are measured at amortised cost, which usually corresponds to nominal value.2023-04-24Jack Groth Jacobsen